



National
Library
of Medicine

PubMed Nucleotide Protein Genome Structure PopSet Taxonomy OMIM B

Search for Go Clear

Limits

Preview/Index

History

Clipboard

Details

About Entrez

Display Abstract Sort Save Text Clip Add Order

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journal Browser

MeSH Browser

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

1: Prog Neuropsychopharmacol Biol Psychiatry 1983;7(4-6):443-50

Related Articles, Bool
LinkC

Adenosine receptors in the mammalian central nervous system.

Williams M.

Adenosine by interaction with discrete extracellular recognition sites can modulate cyclic AMP formation and cell firing in the mammalian CNS. The effects of adenosine on cyclic AMP formation are mediated through two extracellular recognition sites: a high affinity ($K_d = 10(-9)$ M) site designated A-1, activation of which results in an inhibition of adenylate cyclase activity and a lower affinity site ($K_d = 10(-6)$ M) designated A-2, activation of which stimulates adenylate cyclase activity. Stable radiolabeled analogs of adenosine have been used to label A-1 receptors in mammalian brain. Adenosine and its stable analogs are potent inhibitors of neurotransmitter release. In addition to being phosphodiesterase inhibitors, the alkylxanthines are also adenosine antagonists, stimulating neurotransmitter release and increasing cell firing by antagonism of the effects of endogenous adenosine. These effects have been attributed to the presence of an inhibitory purinergic tone. Adenosine and related purines have been implicated in the mode of action of several centrally active drugs including anxiolytics, antidepressants and analgesics. Future progress in understanding the potential physiological role of adenosine in the mammalian CNS will depend on the availability of more potent and specific adenosine antagonists, ligands specific for the A₂ receptor, and a better understanding of the factors that regulate adenosine availability.

PMID: 6320295 [PubMed - indexed for MEDLINE]

Display Abstract Sort Save Text Clip Add Order

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Freedom of Information Act](#) | [Disclaimer](#)

i686-pc-linux-gnu Jul 16 2002 16:34:

BEST AVAILABLE COPY